These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16609626)

  • 1. [Heredity and genetic aspects of Raynaud's disease].
    Pistorius MA; Planchon B; Schott JJ; Lemarec H
    J Mal Vasc; 2006 Feb; 31(1):10-5. PubMed ID: 16609626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and genetic analysis of a large Dutch family with autosomal dominant vascular retinopathy, migraine and Raynaud's phenomenon.
    Terwindt GM; Haan J; Ophoff RA; Groenen SM; Storimans CW; Lanser JB; Roos RA; Bleeker-Wagemakers EM; Frants RR; Ferrari MD
    Brain; 1998 Feb; 121 ( Pt 2)():303-16. PubMed ID: 9549508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients.
    Planchon B; Pistorius MA; Beurrier P; De Faucal P
    Angiology; 1994 Aug; 45(8):677-86. PubMed ID: 8048777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The 3p21.1-p21.3 hereditary vascular retinopathy locus increases the risk for Raynaud's phenomenon and migraine.
    Hottenga JJ; Vanmolkot KR; Kors EE; Kheradmand Kia S; de Jong PT; Haan J; Terwindt GM; Frants RR; Ferrari MD; van den Maagdenberg AM
    Cephalalgia; 2005 Dec; 25(12):1168-72. PubMed ID: 16305605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy of Raynaud's phenomenon.
    Belch JJ; Ho M
    Drugs; 1996 Nov; 52(5):682-95. PubMed ID: 9118818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome aberrations in Raynaud's phenomenon.
    Porciello G; Scarpato R; Storino F; Migliore L; Ferri C; Cagetti F; Morozzi G; Bellisai F; Marcolongo R; Galeazzi M
    Eur J Dermatol; 2004; 14(5):327-31. PubMed ID: 15358572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial aggregation of primary Raynaud's disease.
    Freedman RR; Mayes MD
    Arthritis Rheum; 1996 Jul; 39(7):1189-91. PubMed ID: 8670329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raynaud's phenomenon.
    Wigley FM
    Curr Opin Rheumatol; 1993 Nov; 5(6):773-84. PubMed ID: 8117541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon.
    Kanetaka T; Komiyama T; Onozuka A; Miyata T; Shigematsu H
    Eur J Vasc Endovasc Surg; 2004 Apr; 27(4):414-6. PubMed ID: 15015193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of clotting factors in Hungarian patients with Raynaud's phenomenon.
    Shemirani AH; Szomják E; Balogh E; András C; Kovács D; Acs J; Csiki Z
    Blood Coagul Fibrinolysis; 2011 Jan; 22(1):56-9. PubMed ID: 21157301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Laser Doppler-recorded venoarteriolar reflex in Raynaud's phenomenon.
    Stoyneva Z
    Auton Neurosci; 2004 Nov; 116(1-2):62-8. PubMed ID: 15556839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of Raynaud's phenomenon.
    Herrick AL
    Rheumatology (Oxford); 2005 May; 44(5):587-96. PubMed ID: 15741200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raynaud's phenomenon in primary Sjögren's syndrome.
    Skopouli FN; Talal A; Galanopoulou V; Tsampoulas CG; Drosos AA; Moutsopoulos HM
    J Rheumatol; 1990 May; 17(5):618-20. PubMed ID: 2359071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postocclusive reactive hyperemia in hand-arm vibration syndrome.
    Stoyneva Z
    Int J Occup Med Environ Health; 2016; 29(4):659-66. PubMed ID: 27443761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic inflammation predicts long-term mortality in patients with Raynaud's phenomenon.
    Mueller M; Gschwandtner ME; Gamper J; Giurgea GA; Kiener HP; Perkmann T; Koppensteiner R; Schlager O
    J Intern Med; 2018 Mar; 283(3):293-302. PubMed ID: 29068146
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-stage, genome-wide screen for susceptibility loci in primary Raynaud's phenomenon.
    Susol E; MacGregor AJ; Barrett JH; Wilson H; Black C; Welsh K; Silman A; Ollier B; Worthington J
    Arthritis Rheum; 2000 Jul; 43(7):1641-6. PubMed ID: 10902770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autonomic dysfunction in primary Raynaud's phenomenon.
    Koszewicz M; Gosk-Bierska I; Bilińska M; Podemski R; Budrewicz S; Adamiec R; Słotwiński K
    Int Angiol; 2009 Apr; 28(2):127-31. PubMed ID: 19367242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Methylphenidate and secondary Raynaud's phenomenon].
    Iglesias Otero M; Portela Romero M; Bugarín González R; Ventura Victoria MA
    Semergen; 2013 Sep; 39(6):330-4. PubMed ID: 24034762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial.
    Tucker AT; Pearson RM; Cooke ED; Benjamin N
    Lancet; 1999 Nov; 354(9191):1670-5. PubMed ID: 10568568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral L-arginine can reverse digital necrosis in Raynaud's phenomenon.
    Rembold CM; Ayers CR
    Mol Cell Biochem; 2003 Feb; 244(1-2):139-41. PubMed ID: 12701823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.